The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor
Abstract
P-glycoprotein actively transports structurally unrelated compounds out of cells, conferring the multidrug resistance phenotype in cancer. Tariquidar is a potent, specific, noncompetitive inhibitor of P-glycoprotein. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate binding, inhibition of ATP hydrolysis or both. In clinical trials, tariquidar is tolerable and does not have significant pharmacokinetic interaction with chemotherapy. In patients, inhibition of P-glycoprotein has been demonstrated for 48 h after a single dose of tariquidar. Studies to assess a possible increase in toxicity of chemotherapy and the impact of P-glycoprotein inhibition on tumor response and patient outcome are ongoing. Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
The Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M. (2001) · Genome Research · doi:10.1101/gr.gr-1649r · Cited by 1,113
Pharmacology of drugs that alter multidrug resistance in cancer.
Ford, J. M., & Hait, W. N. (1990) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00045-6 · Cited by 974
Thomas, H., & Coley, H. M. (2003) · Cancer Control · doi:10.1177/107327480301000207 · Cited by 931
Sarkadi, B., Homolya, L., Szakács, G., & Váradi, A. (2006) · Physiological Reviews · doi:10.1152/physrev.00037.2005 · Cited by 726
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
List, A. F., Kopecky, K. J., Willman, C. L., Head, D. R., Persons, D. L., Slovak, M. L., Dorr, R., Karanes, C., Hynes, H. E., Doroshow, J. H., et al. (2001) · Blood · doi:10.1182/blood.v98.12.3212 · Cited by 419
Role of Multidrug Transporters in Pharmacoresistance to Antiepileptic Drugs
Löscher, W., & Potschka, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.1.7 · Cited by 409
Choo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J. J., Wilkinson, G. R., & Kim, R. B. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15144-6 · Cited by 395
Pharmacological Strategies for Overcoming Multidrug Resistance
Nobili, S., Landini, I., Giglioni, B., & Mini, E. (2006) · Current Drug Targets · doi:10.2174/138945006777709593 · Cited by 393
Baer, M. R., George, S. L., Dodge, R. K., O'Loughlin, K. L., Minderman, H., Caligiuri, M. A., Anastasi, J., Powell, B. L., Kolitz, J. E., Schiffer, C. A., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1224.h81602001224_1224_1232 · Cited by 366
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Self-citation(2001) · PubMed · Cited by 350
Pheophorbide a Is a Specific Probe for ABCG2 Function and Inhibition
Robey, R. W., Steadman, K., Polgar, O., Morisaki, K., Blayney, M., Mistry, P., & Bates, S. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3298 · Cited by 350
Self-citationPusztai, L., Wagner, P., Ibrahim, N., Rivera, E., Theriault, R., Booser, D., Symmans, F. W., Wong, F., Blumenschein, G., Fleming, D. R., et al. (2005) · Cancer · doi:10.1002/cncr.21227 · Cited by 302
Karssen, A. M. (2001) · Endocrinology · doi:10.1210/en.142.6.2686 · Cited by 280
Mayer, U., Wagenaar, E., Dorobek, B., Beijnen, J. H., Borst, P., & Schinkel, A. H. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119784 · Cited by 269
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
Wandel, C., Kim, R. B., Kajiji, S. M., Guengerich, P. F., Wilkinson, G. R., & Wood, A. J. J. (1999) · PubMed · Cited by 249
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Kemper, E. M., van Zandbergen, A. E., Cleypool, C. G. J., Mos, H. A., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2003) · PubMed · Cited by 243
Greenberg, P. L., Lee, S. J., Advani, R., Tallman, M. S., Sikic, B. I., Letendre, L., Dugan, K., Lum, B., Chin, D. L., Dewald, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.048 · Cited by 235
Potschka, H., Fedrowitz, M., & Löscher, W. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00423-8 · Cited by 226
Brandt, C., Bethmann, K., Gastens, A. M., & Löscher, W. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.014 · Cited by 221
Van Vliet, E. A., Van Schaik, R., Edelbroek, P. M., Redeker, S., Aronica, E., Wadman, W. J., Marchi, N., Vezzani, A., & Gorter, J. A. (2006) · Epilepsia · doi:10.1111/j.1528-1167.2006.00496.x · Cited by 208
Novel mechanisms of drug resistance in leukemia
Ross, D. (2000) · Leukemia · doi:10.1038/sj.leu.2401694 · Cited by 202
Dalton, W. S., Crowley, J. J., Salmon, S., Grogan, T. M., Laufman, L. R., Weiss, G. R., & Bonnet, J. D. (1995) · Cancer · doi:10.1002/1097-0142(19950201)75:3<815::aid-cncr2820750311>3.0.co;2-r · Cited by 175
Boote, D. J., Dennis, I. F., Twentyman, P. R., Osborne, R. J., Laburte, C., Hensel, S., Smyth, J. F., Brampton, M. H., & Bleehen, N. M. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.610 · Cited by 172
Bates, S. E., Mickley, L. A., Chen, Y. N., Richert, N., Rudick, J., Biedler, J. L., & Fojo, A. T. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.10.4337 · Cited by 163
Self-citationReversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
Roe, M., Folkes, A., Ashworth, P., Brumwell, J., Chima, L., Hunjan, S., Pretswell, I., Dangerfield, W., Ryder, H., & Charlton, P. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00030-x · Cited by 163
Schaich, M., Soucek, S., Thiede, C., Ehninger, G., Illmer, T., & the SHG AML96 study group (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05319.x · Cited by 161
Sandler, A. B., Gordon, M. S., de Alwis, D. P., Pouliquen, I. J., Green, L., Marder, P., Chaudhary, A. K., Fife, K., Battiato, L. A., Sweeney, C. J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0644 · Cited by 151
Kolitz, J. E., George, S. L., Dodge, R. K., Hurd, D. D., Powell, B. L., Allen, S. L., Vélez-García, E., Moore, J. O., Shea, T. C., Hoke, E. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.106 · Cited by 150
Berger, W., Setinek, U., Hollaus, P. H., Zidek, T., Steiner, E., Elbling, L., Cantonati, H., Attems, J., Gsur, A., & Micksche, M. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0653-9 · Cited by 142
Bardelmeijer, H. A., Ouwehand, M., Buckle, T., Huisman, M. T., Schellens, J. H. M., Beijnen, J. H., & van Tellingen, O. (2002) · PubMed · Cited by 135
Agrawal, M., Abraham, J., Balis, F. M., Edgerly, M., Stein, W. D., Bates, S. E., Fojo, T., & Chen, C. C. (2003) · PubMed · Cited by 135
Self-citationRole of multidrug resistance and its pharmacological modulation in acute myeloid leukemia.
List, A. F. (1996) · PubMed · Cited by 132
Abraham, J., Bakke, S., Rutt, A., Meadows, B., Merino, M. J., Alexander, R. H., Schrump, D. S., Bartlett, D., Choyke, P. L., Robey, R. W., et al. (2002) · Cancer · doi:10.1002/cncr.10487 · Cited by 129
Self-citationStewart, A. J., Steiner, J., MELLOWS, G., Laguda, B., Norris, D., & Bevan, P. (2000) · PubMed · Cited by 122
Belpomme, D., Gauthier, S., Pujade-Lauraine, É., Facchini, T., Goudier, M.-J., Krakowski, I., Netter-Pinon, G., Frénay, M., Gousset, C., MARIE, F.-N., et al. (2000) · Annals of Oncology · doi:10.1023/a:1026556119020 · Cited by 118
Expression of drug resistance proteins in breast cancer, in relation to chemotherapy
Linn, S. C., Pinedo, H. M., van Ark-Otte, J., van der Valk, P., Hoekman, K., Honkoop, A. H., Vermorken, J. B., & Giaccone, G. (1997) · International Journal of Cancer · Cited by 112
The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone
Karssen, A. M., Meijer, O. C., van der Sandt, I. C. J., Boer, A. D., de Lange, E. C. M., & de Kloet, E. R. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750251 · Cited by 112
Fischer, V., Rodríguez‐Gascón, A., Heitz, F., Tynes, R. E., Hauck, C., Cohen, D., & Vickers, A. E. M. (1998) · PubMed · Cited by 111
Solary, É., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn, J.-Y. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., et al. (1996) · Blood · doi:10.1182/blood.v88.4.1198.bloodjournal8841198 · Cited by 109
Walker, J., Martin, C., & Callaghan, R. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.09.036 · Cited by 108
Wood, P., Burgess, R., MacGregor, A., & Yin, J. A. L. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb08305.x · Cited by 108
Role of P‐Glycoprotein in the Blood‐Brain Transport of Colchicine and Vinblastine
Drion, N., Lemaire, M., Lefauconnier, J.-M., & Scherrmann, J. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67041688.x · Cited by 104
Wishart, G. C., Bissett, D., Paul, J., Jodrell, D. I., Harnett, A. N., Habeshaw, T., Kerr, D. J., Macham, M. A., Soukop, M., & Leonard, R. C. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1771 · Cited by 102
van Zuylen, L., Sparreboom, A., van der Gaast, A., van der Burg, M. E., van Beurden, V., Bol, C. J., Woestenborghs, R., Palmer, P. A., & Verweij, J. (2000) · PubMed · Cited by 101
Yin, J. A. L., Wheatley, K., Rees, J. K. H., Burnett, A. K., & Party, T. U. M. A. L. W. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.02785.x · Cited by 100
van den Heuvel‐Eibrink, M. M., van der Holt, B., Boekhorst, P. A. W. T., Pieters, R., Schoester, M., Löwenberg, B., & Sonneveld, P. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.3343148.x · Cited by 99
Kemper, E. M., Cleypool, C. G. J., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0720-y · Cited by 97
Fracasso, P. M., Brady, M. F., Moore, D. H., Walker, J. L., Rose, P. G., Letvak, L. A., Grogan, T. M., & McGuire, W. P. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2975 · Cited by 95
Gerrard, G., Payne, E. M., Baker, R. J., Jones, D. T., Potter, M. N., Prentice, H. G., Ethell, M. E., McCullough, H., Burgess, M. A., Mehta, A. B., et al. (2004) · PubMed · Cited by 95
van den Heuvel‐Eibrink, M. M., Wiemer, E. A. C., de Boevere, M. J., van der Holt, B., Vossebeld, P. J. M., Pieters, R., & Sonneveld, P. (2001) · Blood · doi:10.1182/blood.v97.11.3605 · Cited by 95
Bates, S. E., Kang, M. H., Meadows, B., Bakke, S., Choyke, P. L., Merino, M. J., Goldspiel, B. R., Chico, I. M., Smith, T., Chen, C. C., et al. (2001) · Cancer · doi:10.1002/1097-0142(20010915)92:6<1577::aid-cncr1484>3.0.co;2-h · Cited by 92
Self-citationOral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
Millward, M. J., Cantwell, B. M. J., Munro, N. C., Robinson, A. G., Corris, P. A., & Harris, A. L. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.189 · Cited by 91
Phase I Study of Infusional Paclitaxel in Combination With the P-Glycoprotein Antagonist PSC 833
Chico, I. M., Kang, M. H., Bergan, R. C., Abraham, J., Bakke, S., Meadows, B., Rutt, A., Robey, R. W., Choyke, P. L., Merino, M. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.832 · Cited by 90
Self-citationPallis, M., Turzanski, J., Higashi, Y., & Russell, N. H. (2002) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190290026277 · Cited by 89
Solary, É., Drénou, B., Campos, L., de Crémoux, P., Mugneret, F., Moreau, P., Lioure, B., Falkenrodt, A., Witz, B., Bernard, M., et al. (2003) · Blood · doi:10.1182/blood-2002-11-3419 · Cited by 89
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)
Kuppens, I. E. L. M., Bosch, T. M., van Maanen, M. J., Rosing, H., Fitzpatrick, A., Beijnen, J. H., & Schellens, J. H. M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0864-4 · Cited by 87
Choo, E. F., Kurnik, D., Muszkat, M., Ohkubo, T., Shay, S. D., Higginbotham, J. N., Glaeser, H., Kim, R. B., Wood, A. J. J., & Wilkinson, G. R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099648 · Cited by 84
Wattel, Solary, É., Hecquet, B., Caillot, Ifrah, N., Brion, Mahé, Milpied, N. J., Janvier, Guerci, et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00870.x · Cited by 72
Milroy, R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.433 · Cited by 68
Robey, R. W., Bakke, S., Stein, W. D., Meadows, B., Litman, T., Patil, S., Smith, T., Fojo, T., & Bates, S. E. (1999) · Blood · doi:10.1182/blood.v93.1.306 · Cited by 64
Self-citationEdwards, J. E., Brouwer, K. R., & McNamara, P. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2284-2286.2002 · Cited by 63
Marchi, N., Guiso, G., Caccia, S., Rizzi, M., Gagliardi, B., Noè, F. M., Ravizza, T., Bassanini, S., Chimenti, S., Battaglia, G. S., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.07.019 · Cited by 52
Savolainen, J., Edwards, J. E., Morgan, M. E., McNamara, P. J., & Anderson, B. D. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.5.479 · Cited by 43
Warren, K. E., Patel, M. C., McCully, C. L., Montuenga, L. M., & Balis, F. M. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050031 · Cited by 40
Wattel, E., Solary, É., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N. J., Janvier, M., Guerci‐Bresler, A., Rochant, H., et al. (1999) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4811-9_5 · Cited by 33
Visani, G., Milligan, D. W., Leoni, F., Chang, J., Kelsey, S., Marcus, R. E., Powles, R., Schey, S., Covelli, A., Isidori, A., et al. (2001) · Leukemia · doi:10.1038/sj.leu.2402117 · Cited by 33
Wood, L., Palmer, M., Hewitt, J., Urtasun, R. C., Bruera, E. D., Rapp, E., & Thaell, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.100 · Cited by 33
Coley, H. M., Verrill, M. W., Gregson, S. E., Odell, D. E., Fisher, C., & Judson, I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00032-0 · Cited by 32
Imbert, F., Jardin, M., Fernandez, C., Gantier, J.-C., Dromer, F., Baron, G., Mentré, F., van Beijsterveldt, L., Singlas, E., & Gimenez, F. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.319 · Cited by 28
Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar
Fracasso, P. M., Blum, K. A., Ma, M. K., Tan, B. R., Wright, L. P., Goodner, S. A., Fears, C. L., Hou, W., Arquette, M. A., Picus, J., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602653 · Cited by 27
The clinical role of MDR1 gene expression in human lung cancer.
Oka, M., Fukuda, M., Sakamoto, A., Takatani, H., Fukuda, M., Soda, H., & Kohno, S. (1997) · PubMed · Cited by 26
Advani, R. H., Lum, B. L., Fisher, G. A., Halsey, J., Chin, D. L., Jacobs, C., & Sikic, B. I. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi396 · Cited by 25
Wattel, E., Solary, É., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Milpied, N. J., Janvier, M., Guerci‐Bresler, A., Rochant, H., et al. (1999) · Cited by 15
Robert, J. (2004) · PubMed · Cited by 13
Cited by
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Szakács, G., Váradi, A., Özvegy-Laczka, C., & Sarkadi, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.12.010 · Cited by 569
Very important pharmacogene summary
Hodges, L. M., Markova, S. M., Chinn, L. W., Gow, J. M., Kroetz, D. L., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283385a1c · Cited by 436
Miller, D. S., Bauer, B., & Hartz, A. M. S. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07109 · Cited by 392
Metadata
- Authors
- Fox, E., & Bates, S. E.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 447-459
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2152546397
- Cited by
- 350
- References
- 82
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.